LYON, France, Feb. 13, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in high-intensity focused ultrasound (HIFU) for the treatment of prostate cancer, announced today that Marc Oczachowski, Chief Executive Officer, is scheduled to present at the Roth 20th Annual OC Growth Stock Conference at the Ritz Carlton Laguna Niguel in Dana Point, CA on Tuesday, February 19, 2008 at 12:00 p.m. PT.

Management will provide a general corporate update and review of several important milestones, including the expansion of Ablatherm-HIFU technology throughout Europe, a U.S. clinical trial update and the introduction and launch of the next generation Lithotriptor Sonolith I-Sys.

A live Web cast of the presentation will be available on EDAP's Web site at www.edap-tms.com. A replay of the Web cast will be available for 30 days after the date of the presentation.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. EDAP's Ablatherm-HIFU is not approved for the treatment of prostate cancer in the United States and is currently undergoing evaluation in a multicenter Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company please visit http://www.edap-tms.com and http://www.hifu-planet.com or http://urotoday.com/HIFU.

CONTACT:  EDAP TMS SA
          Blandine Confort, Investor Relations / Legal Affairs
          +33 4 72 15 31 72
          bconfort@edap-tms.com

          The Ruth Group
          Investors: 
          Stephanie Carrington
          646-536-7017
          scarrington@theruthgroup.com

          R.J. Pellegrino
          646-536-7009
          rpellegrino@theruthgroup.com